Literature DB >> 11352966

Functional evaluation of plasmin formation in primary breast cancer.

P O Chappuis1, B Dieterich, V Sciretta, C Lohse, H Bonnefoi, S Remadi, A P Sappino.   

Abstract

PURPOSE: Plasmin generation is controlled by the plasminogen activators (PA)/plasmin system, which comprises proteases (urokinase-type PA [uPA] and tissue-type PA [tPA]) and antiproteases (PA inhibitors, PAI-1 and PAI-2). The tumoral content of uPA and PAI-1 has been shown to carry prognostic value in breast cancer; however, because most assays used so far have relied on immunometric determinations, we have explored the enzymatic activities governing plasmin formation in breast cancer specimens. PATIENTS AND METHODS: We applied semiquantitative histochemical zymography to 201 primary breast cancer tissue sections. Enzymatic activities were correlated with histopathologic parameters and clinical outcome. The median follow-up was 91 months.
RESULTS: A wide range of PA-mediated catalytic activities was detected. The overall survival was significantly worse for patients with tumors showing tPA in the lowest quartile of activity (P =.003). The 5-year overall survival of patients with tPA activity in the lowest quartile was 58% compared with 81% for patients with tPA value in the other three quartiles. Tumor size, axillary lymph node metastasis, histologic grade, lymphovascular infiltration, TP53 mutation, and tPA activity were all major risk factors in univariate analysis. tPA activity was an independent prognostic factor in a multivariate Cox regression model, both in the whole population (relative risk = 0.5, 95% confidence interval, 0.3 to 0.9; P =.02) and in the node-negative subgroup (relative risk = 0.2, 95% confidence interval, 0.08 to 0.6; P =.004).
CONCLUSION: By using a zymographic assay performed directly on primary tumor tissue sections, we demonstrate that reduced tPA-mediated plasmin production is an independent adverse prognostic factor in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11352966     DOI: 10.1200/JCO.2001.19.10.2731

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  8 in total

1.  The antiangiogenic agent Neovastat (AE-941) stimulates tissue plasminogen activator activity.

Authors:  Denis Gingras; Dominique Labelle; Carine Nyalendo; Dominique Boivin; Michel Demeule; Chantal Barthomeuf; Richard Béliveau
Journal:  Invest New Drugs       Date:  2004-01       Impact factor: 3.850

2.  Grassystatins D-F, Potent Aspartic Protease Inhibitors from Marine Cyanobacteria as Potential Antimetastatic Agents Targeting Invasive Breast Cancer.

Authors:  Fatma H Al-Awadhi; Brian K Law; Valerie J Paul; Hendrik Luesch
Journal:  J Nat Prod       Date:  2017-10-31       Impact factor: 4.050

3.  Proteolysis of CCN1 by plasmin: functional implications.

Authors:  Usha R Pendurthi; Tien T Tran; Marina Post; L Vijaya Mohan Rao
Journal:  Cancer Res       Date:  2005-11-01       Impact factor: 12.701

4.  Role of plasminogen activator inhibitor-1 in urokinase's paradoxical in vivo tumor suppressing or promoting effects.

Authors:  Yuqi Jing; Krisztina Kovacs; Vittal Kurisetty; Zhijie Jiang; Nick Tsinoremas; Jaime R Merchan
Journal:  Mol Cancer Res       Date:  2012-08-21       Impact factor: 5.852

5.  Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor.

Authors:  Yuqi Jing; Caili Tong; Jin Zhang; Takafumi Nakamura; Ianko Iankov; Stephen J Russell; Jaime R Merchan
Journal:  Cancer Res       Date:  2009-02-10       Impact factor: 12.701

Review 6.  Aberrant Factors of Fibrinolysis and Coagulation in Pancreatic Cancer.

Authors:  Lianghua Fang; Qing Xu; Jun Qian; Jin-Yong Zhou
Journal:  Onco Targets Ther       Date:  2021-01-06       Impact factor: 4.147

7.  uPA is upregulated by high dose celecoxib in women at increased risk of developing breast cancer.

Authors:  Wenyi Qin; Weizhu Zhu; John E Hewett; George Rottinghaus; Yin-Chieh Chen; John T Flynn; Beth Kliethermes; Ferdinando Mannello; Edward R Sauter
Journal:  BMC Cancer       Date:  2008-10-15       Impact factor: 4.430

Review 8.  Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment.

Authors:  J Ribeiro; B Sousa; F Cardoso
Journal:  EJC Suppl       Date:  2013-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.